Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191944 | 0.86 | KDM1A (0.34) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL5174339 | 0.86 | KDM1A (0.39) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL31633769 | 0.86 | KDM1A (0.39) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL29503648 | 0.79 | AHR (0.39) | KDM1AKDM1BAHR | |
| SCHEMBL21834387 | 0.79 | ALDH1A1 (0.35) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL22289313 | 0.79 | AHR (0.39) | KDM1AKDM1BAHR | |
| SCHEMBL22289792 | 0.79 | AHR (0.39) | KDM1AKDM1BAHR | |
| SCHEMBL10193923 | 0.79 | KDM1A (0.33) | KDM1AKDM1B | |
| SCHEMBL30883490 | 0.79 | KDM1A (0.33) | KDM1AKDM1B | |
| SCHEMBL733675 | 0.77 | AHR (0.39) | KDM1AKCNH2KDM1BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629430-B2 | Anthracene derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629430-B2 | Anthracene derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20120138914-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120138914-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120138914-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | SOX18, ANXA1, ANXA11 | KDM1A 917/4885KCNH2 342/4885KDM1B 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.